<scp>IL</scp> ‐ <scp>17A</scp> ‐neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the <scp>CXCL5</scp> / <scp>CXCR2</scp> axis

Chuanxi Zhang, Hui Jin, Yumeng Kang, R Zheng, Ziyan Zhang, Hong Xu, Wenchen Cai, Xuemin Gao, Heliang Liu, Na Mao,

The FASEB Journal · 2024 · 12 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Rosacea is a chronic inflammatory skin disorder that can lead to fibrosis. However, the mechanisms underlying fibrosis in the later stages of rosacea have been less thoroughly investigated. Interleukin-17A (IL-17A) has been implicated in both inflammation and organ fibrosis; however, the effectiveness and mechanism of IL-17A-neutralizing antibodies in the later stages of rosacea-related fibrosis remain unclear. In this study, we induced rosacea-like lesions in mice using LL-37 and administered IL-17A-neutralizing antibodies. The results indicated that the IL-17A-neutralizing antibodies alleviated skin damage, reduced skin thickness, and decreased the secretion of inflammatory factors (TNF-α, CAMP, TLR4, P-NF-kB), angiogenesis-related factors (CD31, VEGF), and the TGF-β1 signaling pathway, along with factors associated with epithelial-mesenchymal transition and the deposition of fibrosis-related proteins (COL1) in the rosacea-like mouse models. Furthermore, the IL-17A-neutralizing antibodies effectively diminished the expression of IL-17, IL-17R, CXCL5, and CXCR2 in the skin. Our findings demonstrate that IL-17A-neutralizing antibodies inhibit the activation of the CXCL5/CXCR2 axis in rosacea-like skin tissue, thereby ameliorating inflammation and fibrosis associated with the condition.

References

23